Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Foundation Medicine < Previous 1 2 Next > U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation October 11, 2024 From Foundation Medicine Via Business Wire Foundation Medicine Awarded Contract by the U.S. Department of Veterans Affairs to Provide Tumor Molecular Profiling to Veterans with Cancer September 24, 2024 From Foundation Medicine Via Business Wire Foundation Medicine Partners with Syndax to Develop a Companion Diagnostic in Hematology and Support Efforts to Pursue Regulatory Approval for an Assay Based on the FoundationOne®Heme Platform September 04, 2024 From Foundation Medicine Via Business Wire U.S. Food and Drug Administration Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Lynparza® (olaparib) in Combination with Abiraterone for Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer September 03, 2024 From Foundation Medicine Via Business Wire Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine’s RNA Platform August 28, 2024 From Foundation Medicine Via Business Wire U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for AKEEGA® (niraparib and abiraterone acetate) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer July 01, 2024 From Foundation Medicine Via Business Wire Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib June 12, 2024 From Foundation Medicine Via Business Wire Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator May 29, 2024 From Foundation Medicine Via Business Wire Tickers PMVP Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO® Annual Meeting May 24, 2024 From Foundation Medicine Via Business Wire Foundation Medicine Launches RNA Sequencing Test, FoundationOne®RNA, in the U.S. May 21, 2024 From Foundation Medicine Via Business Wire Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting March 06, 2024 From Foundation Medicine Via Business Wire Foundation Medicine Appoints Dan Malarek as Chief Executive Officer December 14, 2023 From Foundation Medicine Via Business Wire U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) to Identify Patients with HR-Positive, HER2-Negative Advanced Breast Cancer November 20, 2023 From Foundation Medicine Via Business Wire Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in Non-Small Cell Lung Cancer November 15, 2023 From Foundation Medicine Via Business Wire Foundation Medicine Announces Participation in National Cancer Institute’s ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug Combinations October 26, 2023 From Foundation Medicine Via Business Wire Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings October 21, 2023 From Foundation Medicine Via Business Wire New Research from Foundation Medicine and Roche Demonstrates Improved Outcomes Following Treatment Based on Comprehensive Genomic Profiling in Patients with Cancer of Unknown Primary Origin (CUP) October 20, 2023 From Foundation Medicine Via Business Wire Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting October 19, 2023 From Foundation Medicine Via Business Wire FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Pfizer’s BRAFTOVI® (encorafenib) in Combination With MEKTOVI® (binimetinib) to Identify Patients with BRAF V600E Alterations in Metastatic NSCLC October 12, 2023 From Foundation Medicine Via Business Wire Foundation Medicine and Natera Announce Broad Clinical Launch and Medicare Coverage of FoundationOne®Tracker October 10, 2023 From Foundation Medicine Via Business Wire U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors October 09, 2023 From Foundation Medicine Via Business Wire Foundation Medicine Announces the Launch of FoundationOne®RNA Assay for Research and Investigational Use September 06, 2023 From Foundation Medicine Via Business Wire U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer August 14, 2023 From Foundation Medicine Via Business Wire Foundation Medicine Awards Grant to Moffitt Cancer Center and LUNGevity to Help Remove Barriers to Information About Personalized Oncology for Black Patients July 31, 2023 From Foundation Medicine Via Business Wire Foundation Medicine Announces Leadership Appointments June 15, 2023 From Foundation Medicine Via Business Wire U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer June 09, 2023 From Foundation Medicine Via Business Wire Foundation Medicine Announces Collaboration with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Selected Marketed and Pipeline Treatments June 05, 2023 From Foundation Medicine Via Business Wire Foundation Medicine Expands Monitoring Portfolio with Launch of FoundationOne®Monitor June 02, 2023 From Foundation Medicine Via Business Wire FoundationOne®Liquid CDx Receives FDA-Approval as a Companion Diagnostic for EXKIVITY® (mobocertinib) to Identify Patients with EGFR Exon 20 Insertion Mutations in Advanced Non-Small Cell Lung Cancer May 04, 2023 From Foundation Medicine Via Business Wire Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development April 11, 2023 From Foundation Medicine Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
